APA

Horn L., Gettinger S., Camidge D. R., Smit E. F., Janjigian Y. Y., Miller V. A., Pao W., Freiwald M., Fan J., Wang B., Chand V. K. & Groen H. J. M. (20180625). Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. : Lung cancer (Amsterdam, Netherlands).

Chicago

Horn Leora, Gettinger Scott, Camidge D Ross, Smit Egbert F, Janjigian Yelena Y, Miller Vincent A, Pao William, Freiwald Matthias, Fan Jean, Wang Bushi, Chand Vikram K and Groen Harry J M. 20180625. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. : Lung cancer (Amsterdam, Netherlands).

Harvard

Horn L., Gettinger S., Camidge D. R., Smit E. F., Janjigian Y. Y., Miller V. A., Pao W., Freiwald M., Fan J., Wang B., Chand V. K. and Groen H. J. M. (20180625). Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. : Lung cancer (Amsterdam, Netherlands).

MLA

Horn Leora, Gettinger Scott, Camidge D Ross, Smit Egbert F, Janjigian Yelena Y, Miller Vincent A, Pao William, Freiwald Matthias, Fan Jean, Wang Bushi, Chand Vikram K and Groen Harry J M. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. : Lung cancer (Amsterdam, Netherlands). 20180625.